Biotech
CHICAGO, IL: Revenue Improved 539% and Gross Profit Improved 487% compared to the three months ended June 30, 2016
...
CAMBRIDGE, MASSACHUSETTS: VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology On track to initiate a Phase I/2a clinical study in the second half of 2017
...
TORONTO, ONTARIO: Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable securities of $72.6 million at ...
TORONTO, ONTARIO: $25 Million of Expected Sales, With Approximately $10 Million of New Business
...
CAMBRIDGE, MASSACHUSETTS: Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data af ...
